Sodium-glucose cotransporter 2 (SGLT2) inhibitors

Journal articles and book chapters

06-21-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

06-20-2018 | Ipragliflozin | Article

Ipragliflozin add-on therapy to a GLP-1 receptor agonist in Japanese patients with type 2 diabetes (AGATE): A 52-week open-label study

Ishihara H et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0455-8

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

06-13-2018 | Oral combination medications | Article

A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: Metabolic effects and markers associated with bodyweight loss

Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

06-12-2018 | Empagliflozin | Article

Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

06-12-2018 | Empagliflozin | Article

Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial)

Kuchay MS et al. Diabetes Care 2018: dc180165. doi: 10.2337/dc18-0165

06-09-2018 | Cardiovascular disorders | Review | Article

Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

06-08-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

06-05-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

06-01-2018 | DPP-4 inhibitors | Article

Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

05-25-2018 | Oral combination medications | Article

Characterization of the open-label lead-in period of two randomized controlled phase 3 trials evaluating dapagliflozin, saxagliptin, and metformin in type 2 diabetes

Mathieu C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0445-x

05-24-2018 | Diet | Article

The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure, and renal function in Muslim patients with type 2 diabetes

Shao Y et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.05.022

05-22-2018 | Cardiovascular disorders | Article

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9

05-18-2018 | Type 2 diabetes | Review | Article

Combination glucose-lowering therapy plans in T2DM: Case-based considerations

Blonde L, Dipp S, Cadena D. Adv Ther 2018. doi: 10.1007/s12325-018-0694-0

05-04-2018 | SGLT2 inhibitors | Review | Article

Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes

Zheng et al. JAMA 2018; 319:1580. doi: 10.1001/jama.2018.3024

05-04-2018 | GLP-1 agonists | Review | Article

Glucagon-like peptide 1 in health and disease

Andersen A et al. Nat Rev Endocrinol 2018; Advance online publication. doi: 10.1038/s41574-018-0016-2

04-28-2018 | Heart failure | Review | Article

SGLT2 inhibition and heart failure: Current concepts

Custodio JS et al. Heart Fail Rev 2018; 23: 409–418. doi: 10.1007/s10741-018-9703-2

04-16-2018 | Type 1 diabetes | Review | Article

The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus

Fattah H, Vallon, V. Drugs 2018; 78: 717–726. doi: 10.1007/s40265-018-0901-y

04-09-2018 | SGLT2 inhibitors | Article

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis

Zhang L et al. Diabetes Res Clin Prac 2018; Advance online publication. doi: 10.1016/j.diabres.2018.03.047

04-05-2018 | Oral combination medications | Review | Article

Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk

Goncalves E, Bell DSH. Diabetes Ther 2018; 9: 919–926. doi: 10.1007/s13300-018-0420-6

Next Previous